SAGE Therapeutics (SAGE) Misses Q2 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Sage Therapeutics (SAGE) PT Raised to $95 at Needham & Company
August 4, 2017 7:27 AM EDTNeedham & Company raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $95.00 (from $82.00) while maintaining a Buy rating.
Analyst Danielle Brill commented, "Sage plans to report data from seven trials by YE17. Expected first in 3Q are results from the Brexanolone Phase 3 SRSE trial which... More
